patheon thermo fisher acquisition

Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Thermo Fisher said the acquisition of Patheon will provide the company with entry into the attractive and high growth contract development and manufacturing organization market. For more information, please visit www.thermofisher.com. In August 2017, Thermo Fisher Scientific completed the acquisition of Patheon, creating the world’s most comprehensive and sophisticated end-to-end CDMO partner. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any ordinary shares of Patheon or any other securities, nor is it a substitute for the tender offer materials that Thermo Fisher and its acquisition subsidiary have filed with the SEC. Our Fisher Clinical Services SM offerings are now part of the Patheon brand portfolio by Thermo Fisher Scientific. The offer to purchase all of the outstanding ordinary shares of Patheon is only being made pursuant to the offer to purchase, the letter of transmittal and related documents filed as a part of the Schedule TO. Thermo Fisher Completes $7.2B Patheon Acquisition. Patheon, by Thermo Fisher Scientific, is a leading drug Contract Development & Manufacturing Organization (CDMO) serving more than 400 pharmaceutical clients worldwide. Patheon has invested significantly to become a scale player in the CDMO market and extend its leadership position. Today's close follows the expiration of Thermo Fisher's initial tender offer for Patheon at $35.00 per share in cash. Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced the expiration of the subsequent offering period of its previously announced tender offer to purchase all of the outstanding ordinary shares of Patheon N.V. Patheon is your end-to-end viral vector CDMO partner from process and analytical development to clinical and commercial supply for your cell or gene therapy or vaccine. Patheon Development services ... Thermo Fisher is a trusted partner for every step in the drug development journey with unrivaled quality, reliability, and expertise. Adjusted EPS also excludes certain other gains and losses that are either isolated or cannot be expected to occur again with any regularity or predictability, tax provisions/benefits related to the previous items, benefits from tax credit carryforwards, the impact of significant tax audits or events and the results of discontinued operations. The tender offer referenced herein commenced on May 31, 2017. NEW YORK (GenomeWeb) – Thermo Fisher Scientific said today it has completed its $7.2 billion acquisition of contract development and manufacturing organization (CDMO) Patheon. The tender offer materials (including the offer to purchase and the related letter of transmittal and the other tender offer documents), the solicitation/recommendation statement and other documents filed with the SEC by Thermo Fisher or Patheon may be obtained free of charge at the SEC's website at www.sec.gov or at Patheon's website at www.patheon.com or by contacting Patheon's investor relations department at 919-226-3165 or at Thermo Fisher's website at www.thermofisher.com or by contacting Thermo Fisher's investor relations department at 781-622-1111. ... Thermo Fisher Scientific Inc. announces acquisition of QIAGEN N.V., a leading global provider of molecular diagnostics and sample preparation … Our mission is to enable our customers to make the world healthier, cleaner and safer. Patheon – end-to-end pharma services solutions for every drug development journey ... Thermo Fisher is a trusted partner for every step in the drug development journey with unrivaled quality, reliability, and expertise. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. Patheon does not own any of the licences of the products it manufactures and is often listed as the manufacturer on packaging, with the product licence holder's brand name, product name and corporate … Our Fisher Clinical Services SM offerings are now part of the Patheon brand portfolio by Thermo Fisher Scientific. Thermo Fisher to acquire Patheon $7.2 billion purchase of contract drug maker opens a new business front for the instrument firm by Marc S. Reisch May 17, 2017 | APPEARED IN VOLUME 95, ISSUE 21 The procedures for tendering shares during the subsequent offering period are described in the Schedule TO and are generally the same as those applicable to the initial offering period, except that the guaranteed delivery procedures may not be used during the subsequent offering period and no withdrawal rights will apply to shares tendered during the subsequent offering period. Thermo Fisher continues to expect to realize total synergies of approximately $120 million by year three following the close, consisting of approximately $90 million of cost synergies and approximately $30 million of adjusted operating income benefit from revenue-related synergies. Our Mission is to enable our customers to make the world healthier, cleaner and safer. The close follows the expiration of Thermo Fisher’s initial tender offer for Patheon … Thermo Fisher offered $ 7.2 billion for Patheon acquisition (Source: Pixabay) Waltham/USA — The next step will be a tender offer to acquire all of the issued and outstanding shares of Patheon for $ 35.00 per share in cash. Based on information provided by American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, a total of 138,406,058 Patheon ordinary shares, representing approximately 95.3% of the outstanding Patheon ordinary shares, had been validly tendered and had not been properly withdrawn as of the Expiration Time (excluding 176,509 ordinary shares, representing approximately 0.12% of the aggregate number of ordinary shares outstanding, tendered pursuant to guaranteed delivery procedures that have not yet been delivered in settlement or satisfaction of such guarantee). The board of directors of the two publicly traded companies approved the acquisition in which Thermo Fisher … For the remainder of 2017, the transaction is expected to be approximately $0.09 accretive to adjusted earnings per share1, which includes $0.02 in the third quarter. Words such as "believes," "anticipates," "plans," "expects," "seeks," "estimates," and similar expressions are intended to identify forward-looking statements, but other statements that are not historical facts may also be deemed to be forward-looking statements. We're delighted to welcome our Patheon colleagues to the Thermo Fisher team and excited about the new opportunities we have to help our customers accelerate innovation and enhance productivity by leveraging our combined strengths.". We bring formulation and process development expertise to pursue early-phase goals and establish a scientifically-sound foundation for success in later stages and beyond. "By adding Patheon’s highly complementary CDMO capabilities to our … Dosage Forms, Products. The company completed the acquisition of Patheon on August 29, … On May 31, 2017, a tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and related documents, was filed with the SEC by Thermo Fisher and its acquisition subsidiary and a solicitation/recommendation statement on Schedule 14D-9 was filed with the SEC by Patheon with respect to the tender offer. Thermo Fisher will commence a tender offer to acquire all of the issued and outstanding shares of Patheon for $35.00 per share in cash. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. Patheon. Thermo Fisher Scientific Inc. the world leader in serving science, announced that it has completed its acquisition of Patheon, a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion. Thermo Fisher also anticipates saving approximately $120 million by the third year after completion of the acquisition. Thermo Fisher does not provide GAAP financial measures on a forward-looking basis because we are unable to predict with reasonable certainty and without unreasonable effort items such as the timing and amount of future restructuring actions and acquisition-related charges as well as gains or losses from sales of real estate and businesses, the early retirement of debt and the outcome of legal proceedings. Thermo Fisher's wholly owned subsidiary, Thermo Fisher (CN) Luxembourg S.à r.l., has accepted for payment all shares that were validly tendered and were not properly withdrawn as of the Expiration Time, and payment for such shares will be made promptly in accordance with the terms of the offer. On August 29, 2017, Thermo Fisher Scientific completed its acquisition of Patheon for $7.2 billion. © Copyright 2016 Thermo Fisher Scientific Inc. All rights reserved. Brands. About Patheon. All ordinary shares validly tendered during the subsequent offering period will be immediately accepted for payment, and tendering holders will thereafter promptly be paid the same form and amount of offer consideration as in the initial offering period. "By adding Patheon's highly complementary CDMO capabilities to our leading clinical trials services and bioproduction technologies, we will be an even stronger partner for our pharmaceutical and biotech customers. The timing and amount of these items are uncertain and could be material to Thermo Fisher's results computed in accordance with GAAP. "We’re pleased to complete our acquisition of Patheon and look forward to the significant value this transaction will create for our customers and our shareholders," said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. Goldman Sachs & Co. acted as financial advisor to Thermo Fisher, and Wachtell, Lipton, Rosen & Katz served as legal counsel. While Thermo Fisher may elect to update forward-looking statements at some point in the future, Thermo Fisher specifically disclaims any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing Thermo Fisher's views as of any date subsequent to today. Announcement of the deal resulted in increases in Thermo Fisher and Patheon shares by 0.5% and 33.2%, respectively. One year later, Thermo Fisher’s Pharma Services is delivering integrated drug development and clinical trial services to clients across the globe. Thermo Fisher Scientific Completes Acquisition of Patheon, Annual Meeting 2020 Questions and Answers, GAAP/Non-GAAP Reconciliation and Financial Package, http://www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html. WALTHAM, Mass., Aug. 29, 2017 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has completed its acquisition of Patheon N.V. (NYSE: PTHN), a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical … Brands. The transaction represents a purchase price of approximately $7.2 billion, which includes One year later, Thermo Fisher’s Pharma Services is delivering integrated drug development and clinical trial services to clients across the globe. Today, Thermo Fisher is acquiring approximately 95.3% of Patheon's outstanding ordinary shares. With … In addition, investors and shareholders of Patheon may obtain free copies of the tender offer materials by contacting D.F. Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has completed its acquisition of Patheon N.V. (NYSE: PTHN), a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately … Delisting is likely to reduce significantly the liquidity and marketability of any Patheon ordinary shares that have not been tendered pursuant to the tender offer. © 2020 Thermo Fisher Scientific Inc. All rights reserved. The close follows the expiration of Thermo Fisher’s initial tender offer for Patheon … and DURHAM, N.C., May 15, 2017 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of directors have approved Thermo Fisher's acquisition of Patheon. Durham-based Patheon N.V., a global provider of pharmaceutical development and manufacturing services that has a large production facility in Greenville, will be acquired by Thermo Fisher Scientific in a deal worth about $5.2 billion.. WALTHAM, Mass., Aug. 29, 2017 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has completed its acquisition of Patheon N.V. (NYSE: PTHN), a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion. Process Development, Validation & Scale Up, Starting Materials, Intermediates & API Sourcing, Clinical Batch Supply (Phase I, II & III), Clinical Batch Supply (Phase I, II, & III), Pre-Clinical & Clinical cGMP Manufacturing, Commercial Process Characterization & Validation, Project Management & Supply Chain Leaders, Investigator Initiated Trial (IIT) Supply Chain Management, ProSyries Pre-Filled Syringe Assembly & Labeling, Starting Materials, Intermediates, & API Sourcing. Details of the 2017 impact will be provided during Thermo Fisher's third quarter earnings call in late October. Additional Information and Where to Find It. Large Molecule Biologics Commercialization. Thermo Fisher Scientific provides industry leading CDMO services as well as clinical trial solutions. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent and pending acquisitions, including the acquisition of Patheon, may not materialize as expected; difficulty retaining key employees; and our ability to successfully implement integration strategies or to achieve expected synergies and operating efficiencies within the expected time-frames or at all. and DURHAM, N.C., May 15, 2017 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of directors have approved Thermo Fisher's acquisition of Patheon. In August 2017, Thermo Fisher Scientific completed the acquisition of Patheon, creating the world’s most comprehensive and sophisticated end-to-end CDMO partner. King & Co., Inc., Thermo Fisher's information agent for the tender offer. Patheon – end-to-end pharma services solutions for every drug development journey ... Thermo Fisher is a trusted partner for every step in the drug development journey with unrivaled quality, reliability, and expertise. Patheon, by Thermo Fisher Scientific, has state-of-the-art development and manufacturing facilities throughout North America, Europe and Australia.

Msi Motherboard X570, Bdo Oquilla Eye Quest, Food Manufacturing Jobs Near Me, Flowers Safe For Dogs, Canon Eos 5d Mark Iii,

Leave a review